Journal Article
. 2019 May;20(6).
doi: 10.1016/S1470-2045(19)30097-X.

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Kenji Tamura 1 Junji Tsurutani 2 Shunji Takahashi 3 Hiroji Iwata 4 Ian E Krop 5 Charles Redfern 6 Yasuaki Sagara 7 Toshihiko Doi 8 Haeseong Park 9 Rashmi K Murthy 10 Rebecca A Redman 11 Takahiro Jikoh 12 Caleb Lee 12 Masahiro Sugihara 13 Javad Shahidi 12 Antoine Yver 12 Shanu Modi 14 
  • PMID: 31047803
  •     25 citations


Background: Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent topoisomerase I inhibitor payload. A phase 1, non-randomised, open-label, multiple-dose study was done to assess the safety, tolerability, and activity of trastuzumab deruxtecan in HER2-expressing, advanced solid tumours. The dose escalation (part 1) has previously been reported and the recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg were established. In this Article, we report the safety and preliminary activity results from this phase 1 trial in all patients with HER2-positive advanced-stage breast cancer with previous trastuzumab emtansine treatment who received trastuzumab deruxtecan at the recommended doses for expansion.

Methods: We did an open-label, dose-escalation and dose-expansion phase 1 trial at eight hospitals and clinics in the USA and six in Japan. Eligible patients were at least 18 years old in the USA and at least 20 years of age in Japan and had advanced solid tumours (regardless of HER2 expression in dose escalation or HER2 expression or mutation in dose expansion). The recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg trastuzumab deruxtecan were administered intravenously to patients once every 3 weeks until withdrawal of consent, unacceptable toxicity, or progressive disease. In this Article, all patients with HER2-positive advanced-stage breast cancer with previous trastuzumab emtansine treatment who received trastuzumab deruxtecan at the recommended doses for expansion were analysed together. The primary endpoints of the study were safety and preliminary activity (proportion of patients who achieved an objective response as assessed by the investigators). The activity evaluable set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion, and for whom both baseline and post-treatment activity data were available. The safety analysis set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion. Enrolment for patients with HER2-positive breast cancer has been completed. This trial is registered at, number NCT02564900, and, number JapicCTI-152978.

Findings: Between Aug 28, 2015, and Aug 10, 2018, 115 of 118 patients with HER2-positive breast cancer were treated with at least one dose of trastuzumab deruxtecan at the recommended doses for expansion. All patients had at least one treatment-emergent adverse event. Frequent grade 3 or worse treatment-emergent adverse events included anaemia (19 [17%] of 115) and decreased neutrophil (16 [14%]), white blood cell (ten [9%]), and platelet (nine [8%]) counts. At least one serious treatment-emergent adverse event occurred for 22 (19%) patients. Investigators reported 20 cases of interstitial lung disease, pneumonitis, or organising pneumonia, including one grade 3 event and two treatment-related deaths due to pneumonitis. One death unrelated to study treatment was due to progressive disease. 66 (59·5%; 95% CI 49·7-68·7) of 111 patients had a confirmed objective response.

Interpretation: Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activity in trastuzumab emtansine-pretreated patients with HER2-positive breast cancer. These results suggest that further development in phase 2 and 3 clinical trials for HER2-positive breast cancer is warranted.

Funding: Daiichi Sankyo Co, Ltd.

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
Tomomi Nakayama Iwata, Kiyoshi Sugihara, Teiji Wada, Toshinori Agatsuma.
PLoS One, 2019 Oct 02; 14(10). PMID: 31574081    Free PMC article.
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.
Mary-Ann Bjornsti, Scott H Kaufmann.
F1000Res, 2019 Oct 12; 8. PMID: 31602296    Free PMC article.
Targeted Therapies for Triple-Negative Breast Cancer.
Tomas G Lyons.
Curr Treat Options Oncol, 2019 Nov 23; 20(11). PMID: 31754897
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.
Koji Haratani, Kimio Yonesaka, +15 authors, Kazuhiko Nakagawa.
J Clin Invest, 2019 Oct 30; 130(1). PMID: 31661465    Free PMC article.
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
Alberto Ocaña, Eitan Amir, Atanasio Pandiella.
Breast Cancer Res, 2020 Feb 02; 22(1). PMID: 32005279    Free PMC article.
Antibody-Drug Conjugates in Urothelial Carcinomas.
Michal Sarfaty, Jonathan E Rosenberg.
Curr Oncol Rep, 2020 Feb 03; 22(2). PMID: 32008109
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.
Rita De Santis.
MAbs, 2020 Feb 15; 12(1). PMID: 32054397    Free PMC article.
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
Francis W Hunter, Hilary R Barker, +5 authors, Stephen M F Jamieson.
Br J Cancer, 2019 Dec 17; 122(5). PMID: 31839676    Free PMC article.
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.
Ricardo L B Costa, Brian J Czerniecki.
NPJ Breast Cancer, 2020 Mar 21; 6. PMID: 32195333    Free PMC article.
Trastuzumab Deruxtecan: First Approval.
Susan J Keam.
Drugs, 2020 Mar 08; 80(5). PMID: 32144719
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.
Regina Padmanabhan, Hadeel Shafeeq Kheraldine, +2 authors, Ala-Eddin Al Moustafa.
Cancers (Basel), 2020 Mar 14; 12(3). PMID: 32164163    Free PMC article.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
Diana Lüftner, Andreas Schneeweiss, +16 authors, Michael P Lux.
Geburtshilfe Frauenheilkd, 2020 Apr 24; 80(4). PMID: 32322108    Free PMC article.
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Bob T Li, Flavia Michelini, +46 authors, Maurizio Scaltriti.
Cancer Discov, 2020 Mar 28; 10(5). PMID: 32213539    Free PMC article.
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Jordyn Kreutzfeldt, Brett Rozeboom, Nandini Dey, Pradip De.
Am J Cancer Res, 2020 May 06; 10(4). PMID: 32368385    Free PMC article.
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi, Haeseong Park, +14 authors, Shunji Takahashi.
J Clin Oncol, 2020 Feb 15; 38(17). PMID: 32058843    Free PMC article.
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi.
Essia Mezni, Cécile Vicier, +3 authors, Anthony Gonçalves.
Cancers (Basel), 2020 Jun 18; 12(6). PMID: 32545895    Free PMC article.
Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer.
Shivaprasad Gadag, Shristi Sinha, +2 authors, Usha Y Nayak.
Pharmaceutics, 2020 Jun 12; 12(6). PMID: 32521684    Free PMC article.
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Michelle D Hackshaw, Heather E Danysh, +6 authors, Charles A Powell.
Breast Cancer Res Treat, 2020 Jun 28; 183(1). PMID: 32591987    Free PMC article.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Shanu Modi, Cristina Saura, +23 authors, DESTINY-Breast01 Investigators.
N Engl J Med, 2019 Dec 12; 382(7). PMID: 31825192    Free PMC article.
Highly Cited.
Toward a More Precise Future for Oncology.
Yonina R Murciano-Goroff, Barry S Taylor, David M Hyman, Alison M Schram.
Cancer Cell, 2020 Apr 15; 37(4). PMID: 32289268    Free PMC article.
Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment.
Rurina Watanuki, Akihiko Shimomura, +9 authors, Kenji Tamura.
Medicine (Baltimore), 2020 Sep 23; 99(38). PMID: 32957402    Free PMC article.
Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.
Fleury Augustin Nsole Biteghe, Neelakshi Mungra, +6 authors, Stefan Barth.
Oncotarget, 2020 Oct 06; 11(38). PMID: 33014289    Free PMC article.
Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand?
Pankaj G Roy, Didier Verhoeven.
Gland Surg, 2020 Nov 24; 9(5). PMID: 33224790    Free PMC article.
Breast Cancer Heterogeneity and Response to Novel Therapeutics.
Mariona Baliu-Piqué, Atanasio Pandiella, Alberto Ocana.
Cancers (Basel), 2020 Nov 11; 12(11). PMID: 33167363    Free PMC article.